AI Terminal
Pentixapharm Holding AG
Report Publication Announcement • Apr 15, 2025
8205_rns_2025-04-15_9896cd75-0bd8-47a3-b105-e9910871f9ce.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 15 April 2025 08:17
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
Pentixapharm Holding AG / Key word(s): Annual Report/Annual Results
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
15.04.2025 / 08:17 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions:
- The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements.
- Based on current planning, the Company expects a net loss of approximately EUR 23.5 million for the 2025 financial year.
This forecast reflects expected research and development expenses of around EUR 11 million and personnel and other operating expenses of around EUR 9.5 million. Potential revenues from out-licensing activities are not included in the forecast.
The full Annual Report for the 2024 financial year was published today, on April 15, 2025. The Company will host an investor call to present the financial results at 2:00 p.m. CEST on the same day. Registration is available at the following link:
About Pentixapharm
Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
For more information, please contact:
Pentixapharm Holding AG
Phillip Eckert, Investor Relations
Tel. +49 30 94893232
15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | [email protected] |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2117758 |
| End of News | EQS News Service |
2117758 15.04.2025 CET/CEST